Tetralogic Pharmaceuticals Corp., of Paoli, Pa., and its wholly owned subsidiary said they completed the sale to Medivir AB, of Stockholm, of the SMAC mimetic program, including clinical-stage asset birinapant and topical HDAC inhibitor remetinostat.